Astilbin prevents bone loss in ovariectomized mice through the inhibition of RANKL-induced osteoclastogenesis

Haiming Jin, Qingqing Wang, Kai Chen, Ke Xu, Hao Pan, Feifan Chu, Zhen Ye, Ziyi Wang, Jennifer Tickner, Heng Qiu, Chao Wang, Jacob Kenny, Huazi Xu, Te Wang, Jiake Xu

Research output: Contribution to journalArticlepeer-review

16 Citations (Scopus)


Osteoporosis is the most common osteolytic disease characterized by excessive osteoclast formation and resultant bone loss, which afflicts millions of patients around the world. Astilbin, a traditional herb, is known to have anti-inflammatory, antioxidant and antihepatic properties, but its role in osteoporosis treatment has not yet been confirmed. In our study, astilbin was found to have an inhibitory effect on the RANKL-induced formation and function of OCs in a dose-dependent manner without cytotoxicity. These effects were attributed to its ability to suppress the activity of two transcription factors (NFATc1 and c-Fos) indispensable for osteoclast formation, followed by inhibition of the expression of bone resorption-related genes and proteins (Acp5/TRAcP, CTSK, V-ATPase-d2 and integrin β3). Furthermore, we examined the underlying mechanisms and found that astilbin repressed osteoclastogenesis by blocking Ca2+ oscillations and the NF-κB and MAPK pathways. In addition, the therapeutic effect of MA on preventing bone loss in vivo was further confirmed in an ovariectomized mouse model. Therefore, considering its ability to inhibit RANKL-mediated osteoclastogenesis and the underlying mechanisms, astilbin might be a potential candidate for treating osteolytic bone diseases.

Original languageEnglish
Pages (from-to)8355-8368
Number of pages14
JournalJournal of Cellular and Molecular Medicine
Issue number12
Publication statusPublished - 1 Dec 2019


Dive into the research topics of 'Astilbin prevents bone loss in ovariectomized mice through the inhibition of RANKL-induced osteoclastogenesis'. Together they form a unique fingerprint.

Cite this